

## Fullerenol Nanoparticles Suppress RANKL-Induced

## Osteoclastogenesis by Inhibiting Differentiation and Maturation


Huan Geng<sup>a,b</sup>, Ya-Nan Chang<sup>b</sup>, Xue Bai<sup>b,c</sup>, Shuitao Liu<sup>a</sup>, Qing Yuan<sup>b,c</sup>, Weihong Gu<sup>b,c</sup>, Juan Li<sup>b</sup>, Kui Chen<sup>b</sup>, Gengyan Xing<sup>a\*</sup> and Gengmei Xing<sup>b\*</sup>

*a.* Department of Orthopedics, General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China.

*b.* CAS Key Laboratory for Biomedical Effects of Nanomaterial & Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing 100049, China.

*c.* University of Chinese Academy of Sciences, Beijing 100049, China.

\* Corresponding authors: [xingqm@ihep.ac.cn](mailto:xingqm@ihep.ac.cn)



**Fig. S1** Fullerenol reduces the migration of pre-osteoclasts. (A) Pre-osteoclasts were grown on 48-well plates, after scratching, the cells were treated with 30 ng/mL M-CSF and 50 ng/mL RANKL, and fullerenol (0, 1, 10, and 50  $\mu\text{M}$ ), the transferred cells were counted. (B) Fullerenol inhibits the migration of pre-osteoclasts. Error bars are mean $\pm$ SD of triplicate experiments, \*\*\* $p < 0.001$ , significant difference as compared to 0  $\mu\text{M}$  fullerenol groups.